Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
2,375
Period ended Sep 30, 2026
Change on a year earlier
+17.3%
2,024 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 2,375 | +17.3% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 2,337 | +13.9% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 2,175 | +32.1% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 2,115 | +19.2% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 2,024 | +15.3% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 2,051 | +15.1% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 1,647 | -8.7% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 1,775 | -1.4% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 1,755 | +0.7% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,782 | -0.6% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,803 | -0.1% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,801 | +3.7% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 1,742 | +3.6% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 1,793 | +3.4% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 1,804 | +3.6% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 1,737 | -2.9% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 1,681 | +0.1% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 1,734 | -3.9% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 1,741 | +1.5% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,789 | +6.7% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 1,680 | +4.7% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 1,804 | +13.7% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 1,715 | +3.4% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 1,676 | +7.0% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 1,605 | +0.6% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 1,587 | +3.2% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 1,658 | +1.8% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 1,566 | +4.4% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 1,595 | +7.0% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,538 | +0.7% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,629 | +4.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 1,500 | -1.6% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,490 | -0.5% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 1,528 | +4.2% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 1,559 | +4.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,524 | +3.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 1,498 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 1,467 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 1,497 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 1,470 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up neuroscience therapeutic area total — worldwide sales ($m)
- Neuroscience Therapeutic Area Total — U.S. sales ($M)1,733 · Q3 2026
- Neuroscience Therapeutic Area Total — International sales ($M)642 · Q3 2026
- Neuroscience Therapeutic Area Total — Worldwide reported growth YoY (%)17.3% · Q3 2026
- Neuroscience Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)17.6% · Q3 2026
- INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M)998 · Q3 2026
- SPRAVATO (esketamine) — Worldwide sales ($M)624 · Q3 2026
- CAPLYTA (lumateperone) — Worldwide sales ($M)398 · Q3 2026
- CONCERTA / methylphenidate — Worldwide sales ($M)143 · Q3 2026
- RISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — Worldwide sales ($M)1 · Q4 2022
- Other Neuroscience medicines — Worldwide sales ($M)212 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_neuroscience
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.